Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer

NCT06085755 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasm

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Afatinib

Sponsor

Jeeyun Lee